Two Observational Studies Link GLP-1 Receptor Agonists to Reduced Breast Cancer Risk in Women with Obesity

Summary

Two observational studies found that GLP-1 receptor agonists (like Ozempic, Wegovy) are associated with reduced breast cancer incidence in women with overweight or obesity. One study of over 100,000 women showed roughly a 30% lower incidence, while a smaller study of 80,000+ high-risk women found a 16% reduction. Researchers describe using GLP-1 drugs for cancer prevention as an exciting new frontier that could revolutionize oncology, though they emphasize the need for randomized clinical trials to confirm these observational findings.

Source

Twitter / XTwo Observational Studies Link GLP-1 Receptor Agonists to Reduced Breast Cancer Risk in Women with Obesitymdsc.pe